Study of an investigational drug for axial spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This trial tests a new oral medication that may reduce inflammation and improve symptoms in people with axial spondyloarthritis. It is in early phases, meaning the drug is still being studied for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with axial spondyloarthritis, including a positive HLA-B27 test and signs of inflammation on an MRI or a high CRP blood test.
- Your disease activity score (ASDAS) is 2.1 or higher.
- You have tried a nonsteroidal anti-inflammatory drug (NSAID) and it did not work well enough, or you could not tolerate it.
- You have not had more than two prior biologic or targeted synthetic DMARDs (for Parts B and D).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to confirm new classification criteria for axial spondyloarthritis, a type of inflammatory arthritis affecting the spine and sacroiliac joints. Participants with chronic back pain lasting at least 3 months and starting before age 45 will undergo a series of tests to see if these new criteria better identify the condition.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
This study is for people recently diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It tests whether a standardized global review and education program can help patients better understand and manage their condition.
This study follows people who were diagnosed with axial spondyloarthritis (axSpA) recently to better understand the condition over time. It’s mainly for adults and teens who can consent and can communicate in English.
This study tests a new medication (called 608) to see if it helps reduce pain and inflammation in people with a type of spinal arthritis that isn't visible on X-rays. If you have persistent back pain and signs of inflammation, this treatment might offer a new option to feel better.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
Hear when a new Axial Spondyloarthritis (AxSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.